SCHEMBL5705111

SCHEMBL5705111

CC(C)(C)OC(=O)N1CCC(c2cn(S(C)(=O)=O)c3ccccc23)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.52
GPR119 Q8TDV5 6/20 0.46
HTR6 P50406 3/20 0.46
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
STS P08842 2/20 0.45
PRKCG P05129 1/20 0.45
PRKCB P05771 1/20 0.45
PRKCA P17252 1/20 0.45
PRKCH P24723 1/20 0.45
PRKCE Q02156 1/20 0.45
PRKCD Q05655 1/20 0.45
NAMPT P43490 1/20 0.44
CCR8 P51685 1/20 0.43
TPSAB1 Q15661 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5705187 0.89 HTR6 (0.60) SCN9AGPR119HTR6
SCHEMBL1570643 0.86 HTR6 (0.58) SCN9AHTR6
SCHEMBL558066 0.84 SCN9A (0.61) SCN9AGPR119CHRM2CHRM4CHRM1
SCHEMBL27322905 0.83 SCN9A (0.50) SCN9AGPR119CHRM2CHRM4CHRM1
SCHEMBL6133467 0.80 GPR119 (0.54) SCN9AGPR119
SCHEMBL6600673 0.78 KCNH2 (0.52) SCN9AGPR119
SCHEMBL14406151 0.78 GPR119 (0.47) SCN9AGPR119HTR6CHRM2CHRM4
SCHEMBL25032332 0.77 HTR6 (0.48) SCN9AGPR119HTR6STSCCR8
SCHEMBL31270546 0.77 HTR6 (0.48) SCN9AGPR119HTR6STSCCR8
SCHEMBL4675927 0.76 GPR119 (0.50) SCN9AGPR119STSNAMPTCCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1691807-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES Astellas Pharma Inc. (JP) 2006-08-23 EP disclosed
US-20050245540-A1 New methods FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
WO-2005056012-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES ASTELLAS PHARMA INC. (JP) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245540-A1 New methods TGFB1, TGFBR1, TGFB2 SCN9A 2148/4885GPR119 150/4885HTR6 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.